Consequently, inhibiting STAT3's activity presents a strategic approach to disrupt these oncogenic pathways and enhance therapeutic efficacy, making it a focal point for developing novel cancer treatments (Arun et al. 2024; Molenda et al. 2023). This evidence concerns the gene STAT3 and cancer.